ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2015
Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 66 citations in OpenAlex.
- Refined ChIP-Seq Protocol for High-Quality Chromatin Profiling in Solid Tissues Using the Complete Genomics/MGI Sequencing Platform.Current protocols · 2025Article
- Functional Assays to Guide Personalized Oncological Treatment of Patients with Soft-Tissue Sarcomas.Cancers · 2025Review
- Article
- Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.NPJ precision oncology · 2025Article
- Development of a generic decision guide for patients in oncology: a qualitative interview study.BMC medical informatics and decision making · 2025Article
- Navigating the Collective: Nanoparticle-Assisted Identification of Leader Cancer Cells During Migration.Life (Basel, Switzerland) · 2025Article
- Metabolism in the tumor microenvironment: implications for pathogenesis and therapeutics.Frontiers in immunology · 2025Review
- Health equity innovation in precision medicine: data stewardship and agency to expand representation in clinicogenomics.Health research policy and systems · 2024Article
- The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2024Review
- Lightweight Low-Rank Adaptation Vision Transformer Framework for Cervical Cancer Detection and Cervix Type Classification.Bioengineering (Basel, Switzerland) · 2024Article
- Multi-Gene Next-Generation Sequencing Panel for Analysis ofInternational journal of molecular sciences · 2023Article
- DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review.Cancers · 2023Review
- Article
- Unravelling the tumour genome: The evolutionary and clinical impacts of structural variants in tumourigenesis.The Journal of pathology · 2022Review
- The History and Future of Basic and Translational Cell-Free DNA Research at a Glance.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Recommendations for Specimen and Therapy Selection in Colorectal Cancer.Oncology and therapy · 2021Article
- Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions.Oncotarget · 2021Review
- Clinical cancer genomic profiling.Nature reviews. Genetics · 2021Review
- Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.JCO precision oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Advances in tumor genome sequencing have enabled discovery of actionable alterations leading to novel therapies. Currently, there are approved targeted therapies across various tumors that can be matched to genomic alterations, such as point mutations, gene amplification, and translocations. Tools to detect these genomic alterations have emerged as a result of decreasing costs and improved throughput enabled by next-generation sequencing (NGS) technologies. NGS has been successfully utilized for developing biomarkers to assess susceptibility, diagnosis, prognosis, and treatment of cancers. However, clinical application presents some potential challenges in terms of tumor specimen acquisition, analysis, privacy, interpretation, and drug development in rare cancer subsets. Although whole-genome sequencing offers the most complete strategy for tumor analysis, its present utility in clinical care is limited. Consequently, targeted gene capture panels are more commonly employed by academic institutions and commercial vendors for clinical grade cancer genomic testing to assess molecular eligibility for matching therapies, whereas whole-exome and transcriptome (RNASeq) sequencing are being utilized for discovery research. This review discusses the strategies, clinical challenges, and opportunities associated with the application of cancer genomic testing for precision cancer medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.